TSX Penny Stocks To Watch In August 2026

The Canadian market has recently been influenced by rising long-term bond yields, which have weighed on investor sentiment and led to a dip in stock prices. Despite these challenges, penny stocks continue to offer intriguing opportunities for those interested in smaller or newer companies. While the term "penny stocks" may seem outdated, these investments can provide growth potential at lower price points when backed by strong financial health and solid fundamentals.

Here's a peek at a few of the choices from the screener.

DIRTT Environmental Solutions (TSX:DRT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: DIRTT Environmental Solutions Ltd. operates in the industrialized construction sector across the United States and Canada, with a market cap of CA$161.30 million.

Operations: The company's revenue is primarily generated from its Building Products segment, totaling $171.38 million.

Market Cap: CA$161.3M

DIRTT Environmental Solutions, with a market cap of CA$161.30 million, has shown signs of financial improvement despite being unprofitable. The company reported Q2 2026 revenue of US$40.31 million and net income of US$1.06 million, a notable turnaround from a loss the previous year. However, it recently downgraded its 2026 revenue guidance to between US$175-185 million. DIRTT's short-term assets exceed both its short and long-term liabilities, indicating solid liquidity management. Despite increased debt levels over five years, its net debt to equity ratio remains satisfactory at 7.9%, offering some stability in the volatile penny stock space.

• Navigate through the intricacies of DIRTT Environmental Solutions with our comprehensive balance sheet health report here.
• Gain insights into DIRTT Environmental Solutions' outlook and expected performance with our report on the company's earnings estimates.

NexgenRx (TSXV:NXG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: NexgenRx Inc. operates in Canada, providing administration, adjudication, and payment services for drug, dental, and extended health-care claims for beneficiaries of health benefit plans, with a market cap of CA$46.94 million.

Operations: NexgenRx Inc. does not report specific revenue segments.

Market Cap: CA$46.94M

NexgenRx Inc., with a market cap of CA$46.94 million, has demonstrated significant earnings growth, reporting a net income of CA$0.99 million for Q2 2026 compared to CA$0.35 million the previous year. The company's short-term assets comfortably cover both short and long-term liabilities, highlighting strong liquidity management. With no debt and high-quality earnings, NexgenRx's return on equity is robust at 28%. Despite past profit declines averaging 26.2% annually over five years, recent growth of 190.5% underscores its potential in the penny stock sector while maintaining stable shareholder equity without dilution concerns over the past year.

• Jump into the full analysis health report here for a deeper understanding of NexgenRx.
• Gain insights into NexgenRx's historical outcomes by reviewing our past performance report.

Auxly Cannabis Group (TSX:XLY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Auxly Cannabis Group Inc. is a consumer-packaged goods company specializing in cannabis products in Canada, with a market cap of CA$325.19 million.

Operations: The company's revenue segment includes CA$165.57 million from its venture capital activities.

Market Cap: CA$325.19M

Auxly Cannabis Group Inc., with a market cap of CA$325.19 million, has shown stable financial management in the penny stock sector. Despite a slight decline in net profit margins from 20.1% to 19.7%, the company maintains satisfactory debt levels, with net debt to equity at 2.6%. Auxly's short-term assets exceed both its short and long-term liabilities, ensuring strong liquidity. Recent earnings reports indicate revenue growth from CA$38.8 million to CA$45.8 million year-over-year for Q2 2026, although net income slightly decreased from CA$8.31 million to CA$7.7 million, reflecting mixed performance dynamics amidst ongoing share buybacks and strategic financial maneuvers like stock splits.

• Get an in-depth perspective on Auxly Cannabis Group's performance by reading our balance sheet health report here.
• Assess Auxly Cannabis Group's future earnings estimates with our detailed growth reports.

Next Steps

• Click here to access our complete index of 328 TSX Penny Stocks.
• Ready For A Different Approach? AI is about to change healthcare. These 131 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com